By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.




CEO: Ed Kaye, M.D.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT


Company News
Sarepta (SRPT) Gets No Love From the FDA's New Drugs Director 10/20/2016 5:54:08 AM
SunTrust Managing Director Goes Over Sarepta (SRPT)' Story 10/18/2016 7:48:23 AM
Sarepta (SRPT) Lands a Valuable Priority Review Voucher on Exondys 51 OK 10/14/2016 8:29:47 AM
PTC Therapeutics (PTCT) Wants a Slice of Sarepta (SRPT)'s DMD Pie, Says Rejected Drug May Help Some Patients 10/7/2016 7:51:59 AM
Sarepta (SRPT) Goes for a New DMD Combo With New $562 Million+ Deal With Summit Therapeutics 10/4/2016 5:53:42 AM
Sarepta (SRPT) Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping 9/29/2016 10:27:15 AM
Catabasis (CATB) And Sarepta (SRPT) Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy 9/29/2016 9:27:16 AM
Sarepta (SRPT) Announces Pricing Of $300 Million Public Offering Of Common Stock 9/23/2016 9:57:04 AM
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too 9/23/2016 7:40:10 AM
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study 9/23/2016 6:29:16 AM